Visnadine, Prenylflavonoids and Bovine Colostrum to Treat Vulvovaginal Atrophy in Postmenopausal Women
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The effects of a new vaginal cream containing visnadine (0.30%), prenylflavonoids (0.10%) and
bovine colostrum (1%) will be evaluated in post-menopausal sexually active women affected by
vulvovaginal atrophy (VVA).
In a prospective cohort study, post-menopausal women affected by VVA will be enrolled. All
women will undergo vaginal health index score (VHIS) evaluation and will complete the female
sexual function index (FSFI) questionnaire at baseline evaluation (T0) and following 15 days
of vaginal cream treatment with one application per day (T1). All the side effects will be
recorded and an independent data safety and monitoring committee will evaluate the results of
the study.